ライフサイエンスコーパス: antiinflammatory drug

1 a new target of indomethacin, a widely used antiinflammatory drug.

2 of death was 0.68 for users of nonsteroidal antiinflammatory drugs.

3 ts this emerging issue in patients requiring antiinflammatory drugs.

4 , even in the absence of recent nonsteroidal antiinflammatory drugs.

5 are the therapeutic targets of nonsteroidal antiinflammatory drugs.

6 RA) and its response to chronic nonsteroidal antiinflammatory drugs.

7 th chemical gastritis caused by nonsteroidal antiinflammatory drugs.

8 ynthesis and are the targets of nonsteroidal antiinflammatory drugs.

9 d is potently inhibited by some nonsteroidal antiinflammatory drugs.

10 patients following ingestion of nonsteroidal antiinflammatory drugs.

11 both low-dose aspirin and other nonsteroidal antiinflammatory drugs.

12 get for the discovery and development of new antiinflammatory drugs.

13 tential targets for the development of novel antiinflammatory drugs.

14 additional approaches to the development of antiinflammatory drugs.

15 OX-1 inhibition associated with nonsteroidal antiinflammatory drugs.

16 target of antineoplastic, antimicrobial, and antiinflammatory drugs.

17 interfere with PGE2 synthesis, as effective antiinflammatory drugs.

18 a prime therapeutic target for analgesic and antiinflammatory drugs.

19 to treatment with allopurinol, steroids, and antiinflammatory drugs.

20 ts this emerging issue in patients requiring antiinflammatory drugs.

21 herapy for paucibacillary leprosy along with antiinflammatory drugs.

22 s of the indomethacin family of nonsteroidal antiinflammatory drugs.

23 esthetics block neurons, but are also potent antiinflammatory drugs.

24 patients received prescription nonsteroidal antiinflammatory drugs, 58% received opioids, and 50% re

25 Antiinflammatory drugs achieve their therapeutic actions

26 ain mimic suggests an intracellular site for antiinflammatory drug action.

27 acrophage inhibitory cytokine-1/nonsteroidal antiinflammatory drug-activated gene-1 promoter by 2-5A

28 acrophage inhibitory cytokine-1/nonsteroidal antiinflammatory drug-activated gene-1, a TGF-beta super

29 onservative treatment (CT) with nonsteroidal antiinflammatory drugs alone.

30 tic drugs, corticosteroids, and nonsteroidal antiinflammatory drugs, alone or in combination.

31 analogues of diclofenac (1), a nonsteroidal antiinflammatory drug and known inhibitor of transthyret

32 corticoids have great clinical importance as antiinflammatory drugs and can act as potent inducers of

33 are pharmacological targets of nonsteroidal antiinflammatory drugs and cyclooxygenase (COX) 2 inhibi

34 In contrast, opioids, non-steriodal antiinflammatory drugs and cyclooxygenase-2 inhibitors h

35 ns for the perioperative use of nonsteroidal antiinflammatory drugs and glucocorticoids have the most

36 ths and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-

37 properties yet differs from the nonsteroidal antiinflammatory drugs and inhibitors of prostaglandin H

38 Stable dosages of nonsteroidal antiinflammatory drugs and low-dose prednisone were allo

39 discontinued; stable dosage of nonsteroidal antiinflammatory drugs and oral corticosteroids (</=10 m

40 ll count, and use of nonaspirin nonsteroidal antiinflammatory drugs and other medications, subjects w

41 ction of 15-LOX-1 expression by nonsteroidal antiinflammatory drugs and related agents.

42 y in cells were detected: three nonsteroidal antiinflammatory drugs and the thyroid hormone 3,3',5-tr

43 Therapy with nonsteroidal antiinflammatory drugs and traditionally used disease-mo

44 g medications in chronic gout, 2) the use of antiinflammatory drugs, and 3) counseling on lifestyle m

45 iovascular risk factors, use of nonsteroidal antiinflammatory drugs, and a history of gastric or duod

46 some medications, particularly nonsteroidal antiinflammatory drugs, and has been associated with aut

47 of visiting a physician, using analgesic or antiinflammatory drugs, and having arthroplasty (P < 0.0

48 n-converting enzyme inhibitors, nonsteroidal antiinflammatory drugs, and immunosuppressive drugs.

49 We found that widely used antiinflammatory drugs antagonize both biochemical and b

50 enocarcinoma but did agree that nonsteroidal antiinflammatory drugs are associated with a cancer risk

51 Nonsteroidal antiinflammatory drugs are used in rheumatoid arthritis

52 otentially game-changing in the nonsteroidal antiinflammatory drug arena.

53 The common antiinflammatory drug aspirin can reduce inflammasome ac

54 esis and are the targets of the nonsteroidal antiinflammatory drugs aspirin and ibuprofen and the COX

55 s at 100 mug/mL was similar to non-steroidal antiinflammatory drugs aspirin, ibuprofen and naproxen,

56 ygenases, the central action of nonsteroidal antiinflammatory drugs (but not a prominent effect of st

57 ncer chemoprotective effects of nonsteroidal antiinflammatory drugs by defining a mechanism through w

58 Nonsteroidal antiinflammatory drugs can cause regression of adenomas,

59 h prednisolone, methotrexate, 3 nonsteroidal antiinflammatory drugs (celecoxib, diclofenac, and indom

60 hways and the target of cytokine-suppressing antiinflammatory drugs (CSAIDs).

61 ctive lipid mediators via COX-2-nonsteroidal antiinflammatory drug-dependent oxygenations and cell-ce

62 Important nonsteroidal antiinflammatory drug derivatives such as (+/-)-naproxen

63 rimental concentration depth profiles of the antiinflammatory drug dexamethasone in human skin, we mo

64 -inflammatory drug naproxen or the steroidal antiinflammatory drug dexamethasone.

65 T is considered to be a promising target for antiinflammatory drug discovery.

66 Moreover, treatment of animals with antiinflammatory drugs during epileptogenesis prevented

67 Nonsteroidal antiinflammatory drug enteropathy is a stepwise process

68 aemia are useful indications of nonsteroidal antiinflammatory drug enteropathy.

69 Nonsteroidal antiinflammatory drugs, especially Voltaren, may offer e

70 ow that the R-enantiomer of the nonsteroidal antiinflammatory drug etodolac inhibited tumor developme

71 Given that clinical trials of antiinflammatory drugs for LUTS have been largely unsucc

72 corticosteroids - normally highly effective antiinflammatory drugs - has little therapeutic benefit.

73 Most antiinflammatory drugs have been associated with an incr

74 e catalysis, and a known chemopreventive and antiinflammatory drug, i.e., curcumin, is used for the m

75 a- and gamma-cyclodextrins with nonsteroidal antiinflammatory drugs ibuprofen, naproxen, and flurbipr

76 nitor the therapeutic effectiveness of novel antiinflammatory drugs in future human trials.

77 reate concerns about the use of nonsteroidal antiinflammatory drugs in patients with skeletal injury.

78 re as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammatio

79 is unique among clinically used nonsteroidal antiinflammatory drugs in that it irreversibly inactivat

80 Nonsteroidal antiinflammatory drugs, including ibuprofen, are among t

81 is unclear whether nonselective nonsteroidal antiinflammatory drugs increase or decrease the rate of

82 three solid-state forms of the nonsteroidal antiinflammatory drug indomethacin with ammonia gas.

83 istinguishable from that of the nonsteroidal antiinflammatory drug indomethacin, which blocked the pr

84 ing inflammatory bowel disease, nonsteroidal antiinflammatory drug-induced gut injury, and chemothera

85 e endoscopy studies demonstrate nonsteroidal antiinflammatory drug-induced small bowel erosions, but

86 Nonsteroidal antiinflammatory drugs inhibit the development of prosta

87 n colon cancer cells by certain nonsteroidal antiinflammatory drugs involves increased expression of

88 blockade by two analgesics (the nonsteroidal antiinflammatory drug ketoprofen and the mu-opioid agoni

89 Surprisingly, certain nonsteroidal antiinflammatory drugs known to shift the site of proteo

90 the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related to their inhibitio

91 Existing nonsteroidal antiinflammatory drugs may be safer than originally thou

92 nticoagulants like heparin and non-steroidal antiinflammatory drugs may have a solid basis.

93 This class of nonsteroidal, GR-dependent antiinflammatory drugs may offer a safer alternative to

94 ests that rectally administered nonsteroidal antiinflammatory drugs may reduce the incidence of pancr

95 inhibit PG production, such as nonsteroidal antiinflammatory drugs, may be deleterious for muscle gr

96 idely used to treat OA, such as nonsteroidal antiinflammatory drugs, may have limited efficacy once j

97 oped for the quantitation of the anti-cancer/antiinflammatory drug methotrexate (MTX) and its major m

98 d nature of interactions of two nonsteroidal antiinflammatory drugs, namely aspirin and ibuprofen, in

99 cal studies have shown that the nonsteroidal antiinflammatory drug naproxen may be useful in the trea

100 er and amide derivatives of the nonsteroidal antiinflammatory drug naproxen was designed to have both

101 r novel activities such as hydroxylating the antiinflammatory drug naproxen.

102 r Helicobacter pylori-negative, nonsteroidal antiinflammatory drug-negative ulcer patients?

103 ncer cells with and without the nonsteroidal antiinflammatory drug NS-398 or the histone deacetylase

104 itis: 1) a generic nonselective nonsteroidal antiinflammatory drug (NSAID(NS)) alone; 2) NSAID(NS) pl

105 nt a washout of their analgesic/nonsteroidal antiinflammatory drug (NSAID) agents (duration 5 half-li

106 tudy compared the effect of the nonsteroidal antiinflammatory drug (NSAID) diclofenac, which is the m

107 stine is a more common site for nonsteroidal antiinflammatory drug (NSAID) toxicity than the well-rec

108 les but only modestly decreased nonsteroidal antiinflammatory drug (NSAID) turnover while maintaining

109 ors conducted a cohort study of nonsteroidal antiinflammatory drug (NSAID) use and risk of symptomati

110 Nonsteroidal antiinflammatory drug (NSAID) use is a known risk factor

111 the present study, sulindac, a nonsteroidal antiinflammatory drug (NSAID), was tested for protection

112 of diflunisal, an FDA-approved nonsteroidal antiinflammatory drug (NSAID), were synthesized and eval

113 Nonsteroidal antiinflammatory drug (NSAID)-associated gastropathy is

114 Aspirin, nonsteroidal antiinflammatory drugs (NSAID), and acetaminophen are co

115 tiveness of both currently used nonsteroidal antiinflammatory drugs (NSAIDs) (diclofenac) and novel C

116 Among nonusers of nonsteroidal antiinflammatory drugs (NSAIDs) (Pinteraction = 0.055),

117 whether use of aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) affects risk.

118 to assess the relation between nonsteroidal antiinflammatory drugs (NSAIDs) and 1-year mortality in

119 risk, studies of nonselective, nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen have b

120 Previous studies on nonsteroidal antiinflammatory drugs (NSAIDs) and breast cancer have p

121 ted an inverse relation between nonsteroidal antiinflammatory drugs (NSAIDs) and colon cancer, but fe

122 nt preferences for nonselective nonsteroidal antiinflammatory drugs (NSAIDs) and cyclooxygenase-2 (CO

123 iation between long-term use of nonsteroidal antiinflammatory drugs (NSAIDs) and non-Hodgkin lymphoma

124 data on the association between nonsteroidal antiinflammatory drugs (NSAIDs) and ovarian cancer risk

125 ns have identified a variety of nonsteroidal antiinflammatory drugs (NSAIDs) and structurally related

126 nac or other competitively acting nonsteroid antiinflammatory drugs (NSAIDs) and the enzyme activity

127 a concurrent administration of nonsteroidal antiinflammatory drugs (NSAIDS) and/or low-dose corticos

128 es and because apparently safer nonsteroidal antiinflammatory drugs (NSAIDs) are being produced, we s

129 Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used and fr

130 Although nonsteroidal antiinflammatory drugs (NSAIDs) are ineffective in treat

131 Nonsteroidal antiinflammatory drugs (NSAIDs) block prostanoid biosynt

132 reas treatment with 2 different nonsteroidal antiinflammatory drugs (NSAIDs) blocked neuronal CCEs an

133 Nonsteroidal antiinflammatory drugs (NSAIDs) can inhibit colorectal t

134 stablished that taking multiple nonsteroidal antiinflammatory drugs (NSAIDs) can lead to serious gast

135 The nonsteroidal antiinflammatory drugs (NSAIDs) continue to be important

136 have shown that regular use of nonsteroidal antiinflammatory drugs (NSAIDs) decreases bladder cancer

137 Nonsteroidal antiinflammatory drugs (NSAIDs) form a paradigm for the

138 Nonsteroidal antiinflammatory drugs (NSAIDs) have been reported to an

139 of all its substrates, certain non-steroidal antiinflammatory drugs (NSAIDs) have been shown to selec

140 Here, we show that the nonsteroidal antiinflammatory drugs (NSAIDs) ibuprofen and indomethac

141 Although nonsteroidal antiinflammatory drugs (NSAIDs) in general are passed in

142 All nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the cyclooxygena

143 gic studies suggest that use of nonsteroidal antiinflammatory drugs (NSAIDs) is associated with a red

144 ase-inhibiting (COX-inhibiting) nonsteroidal antiinflammatory drugs (NSAIDs) is often complicated by

145 The cardiovascular safety of nonsteroidal antiinflammatory drugs (NSAIDs) may be influenced by int

146 nal prostaglandin inhibition by nonsteroidal antiinflammatory drugs (NSAIDs) may decrease renal funct

147 ing the possibility that use of nonsteroidal antiinflammatory drugs (NSAIDs) may inhibit the developm

148 dies have suggested that use of nonsteroidal antiinflammatory drugs (NSAIDs) may reduce the risk of b

149 otentially protective effect of nonsteroidal antiinflammatory drugs (NSAIDs) on prostate cancer may o

150 nee monarthritis were compared: nonsteroidal antiinflammatory drugs (NSAIDs) only, NSAID trial follow

151 res of high-risk prescribing of nonsteroidal antiinflammatory drugs (NSAIDs) or selected antiplatelet

152 al studies suggests that use of nonsteroidal antiinflammatory drugs (NSAIDs) reduces risk of colon an

153 ave shown that long-term use of nonsteroidal antiinflammatory drugs (NSAIDs) reduces the risk of deve

154 Although nonsteroidal antiinflammatory drugs (NSAIDs) show great promise as th

155 Both traditional nonsteroidal antiinflammatory drugs (NSAIDs) that inhibit COX-1 and C

156 ntestinal liabilities common to nonsteroidal antiinflammatory drugs (NSAIDs) that might be reduced by

157 Nonsteroidal antiinflammatory drugs (NSAIDs) transcriptionally up-reg

158 etermine whether daily users of nonsteroidal antiinflammatory drugs (NSAIDs) were at lower risk than

159 Different nonsteroidal antiinflammatory drugs (NSAIDs) were used to examine the

160 including coxibs, nonselective nonsteroidal antiinflammatory drugs (NSAIDs), and meloxicam, were pre

161 ostaglandin production, such as nonsteroidal antiinflammatory drugs (NSAIDs), and pharmacologic nitri

162 Acid suppression, nonsteroidal antiinflammatory drugs (NSAIDs), and statins may play a

163 any reason did not differ among nonsteroidal antiinflammatory drugs (NSAIDs), but discontinuations du

164 Many of these nonsteroid antiinflammatory drugs (NSAIDs), but in particular diclo

165 ugs, including D-penicillamine, nonsteroidal antiinflammatory drugs (NSAIDs), calcium channel blocker

166 nhibitors and aspirin, or other nonsteroidal antiinflammatory drugs (NSAIDs), in combination as a str

167 , as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains uncertain.

168 teoarthritis (OA) pain, such as nonsteroidal antiinflammatory drugs (NSAIDs), simple analgesics, and

169 Nonsteroidal antiinflammatory drugs (NSAIDs), such as aspirin, freque

170 4-eicosatetraynoic acid, and in nonsteroidal antiinflammatory drugs (NSAIDs), such as indomethacin an

171 al hemorrhage than nonselective nonsteroidal antiinflammatory drugs (NSAIDs), there has been concern

172 urally occurring flavonols) and nonsteroidal antiinflammatory drugs (NSAIDs).

173 proportion of prescriptions for nonsteroidal antiinflammatory drugs (NSAIDs).

174 ds is more limited than that on nonsteroidal antiinflammatory drugs (NSAIDs).

175 d are the molecular targets for nonsteroidal antiinflammatory drugs (NSAIDs).

176 effects than currently marketed nonsteroidal antiinflammatory drugs (NSAIDs).

177 on was inhibited by aspirin and nonsteroidal antiinflammatory drugs (NSAIDs).

178 1 (PGHS-1) is the target of the nonsteroidal antiinflammatory drugs (NSAIDs).

179 Both isoforms are targets of nonsteroidal antiinflammatory drugs (NSAIDs).

180 MTX), oral glucocorticoids, and nonsteroidal antiinflammatory drugs (NSAIDs).

181 ng the use of aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs).

182 al cancer in relation to use of nonsteroidal antiinflammatory drugs (NSAIDs).

183 rapeutic target for widely used nonsteroidal antiinflammatory drugs (NSAIDs).

184 itors (coxibs) and nonselective nonsteroidal antiinflammatory drugs (NSAIDs).

185 mmon undesirable effects of the nonsteroidal antiinflammatory drugs (NSAIDs).

186 ommon active internal controls (nonsteroidal antiinflammatory drugs [NSAIDs], naproxen) were determin

187 re both targets of nonselective nonsteroidal antiinflammatory drugs (nsNSAIDs) including aspirin wher

188 ent only among those not taking nonsteroidal antiinflammatory drugs (odds ratio = 0.49, 95% CI: 0.25,

189 cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis compared with

190 persons taking aspirin or other nonsteroidal antiinflammatory drugs on a regular basis.

191 To evaluate the effects of antimicrobial and antiinflammatory drugs on oviductal pathology in chronic

192 hylaxis for leishmaniasis or even the use of antiinflammatory drugs or antibiotics may be considered

193 dicated that sulindac and other nonsteroidal antiinflammatory drugs or cyclooxygenase inhibitors have

194 tinue their background doses of nonsteroidal antiinflammatory drugs or disease-modifying antirheumati

195 Use of nonsteroidal antiinflammatory drugs (OR = 1.7, 95% CI 1.0, 2.6), angi

196 term users of aspirin, ethanol, nonsteroidal antiinflammatory drugs, or a combination of these substa

197 tween the use of aspirin, other nonsteroidal antiinflammatory drugs, or acetaminophen and PD risk.

198 to determine whether steroids, nonsteroidal antiinflammatory drugs, or both can prevent or treat the

199 were allowed to continue taking nonsteroidal antiinflammatory drugs, oral corticosteriods (< or =10 m

200 rcinomas, and its inhibition by nonsteroidal antiinflammatory drugs protects against colorectal cance

201 as diminished by an analog of a nonsteroidal antiinflammatory drug (R-etodolac), at concentrations th

202 Tor proteins, targets of the antiinflammatory drug rapamycin, mediate a conserved sig

203 laboratory studies suggest that nonsteroidal antiinflammatory drugs reduce the risk of colon cancer a

204 Nonsteroidal antiinflammatory drugs reduce the risk of colon cancer,

205 ger among participants who used nonsteroidal antiinflammatory drugs regularly (highest vs. lowest qua

206 the start of therapy: age, sex, nonsteroidal antiinflammatory drug-related risk factors for upper gas

207 ition of the COX-2 component by nonsteroidal antiinflammatory drugs restored the apoptotic response.

208 o study the interactions of two nonsteroidal antiinflammatory drugs, salicylate and ibuprofen, with v

209 to the analysis of a mixture of nonsteroidal antiinflammatory drugs separated by reversed-phase HPLC.

210 Whenever possible, antiinflammatory drugs should be given in monotherapy an

211 Nonsteroidal antiinflammatory drugs still remain mainstays of treatme

212 logically important targets for nonsteroidal antiinflammatory drugs, such as aspirin and newer COX-2

213 rsion of carboxylate-containing nonsteroidal antiinflammatory drugs, such as indomethacin, to esters

214 bryos to disordered inflammation; therefore, antiinflammatory drugs, such as low-dose aspirin (LDA),

215 l-2-isopropylpyrazolo-[1,5-a]pyridine) is an antiinflammatory drug that was initially developed for t

216 -neuronal cells are blocked by non-steroidal antiinflammatory drugs that are derivatives of diphenyla

217 e or nonuse of aspirin or other nonsteroidal antiinflammatory drugs; the presence or absence of physi

218 In contrast, when mice were treated with an antiinflammatory drug to prevent microglial activation,

219 cin (INDO) was one of the first nonsteroidal antiinflammatory drugs to be characterized as a time-dep

220 e may be a more common site for nonsteroidal antiinflammatory drug toxicity than the gastroduodenal m

221 Nonsteroidal antiinflammatory drug toxicity to the small intestine is

222 The lack of effective antiinflammatory drug treatment for COPD has thus shifte

223 viously received treatment with nonsteroidal antiinflammatory drugs underwent stratification accordin

224 es in New Jersey, the effect of nonsteroidal antiinflammatory drug use on 1-year all-cause mortality

225 We investigated whether nonsteroidal antiinflammatory drug use was associated with a lower ri

226 physical activity, aspirin and nonsteroidal antiinflammatory drug use, alcohol consumption, and inta

227 Two-thirds of regular nonsteroidal antiinflammatory drug users develop subclinical small bo

228 s (primarily fluoroquinolones), nonsteroidal antiinflammatory drugs (Voltaren and ketorolac), and new

229 d has been shown to be a molecular target of antiinflammatory drugs, we sought to characterize the fu

230 dy medications and avoidance of nonsteroidal antiinflammatory drugs were excellent.

231 of fluids ingested, and use of nonsteroidal antiinflammatory drugs were not.

232 story of inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive 40 mg

233 Nonsteroidal antiinflammatory drugs, which inhibit COX-2, prevent col

234 As an established antiinflammatory drug with neuroprotective properties, m